Cargando…
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
Metformin is, if not contraindicated and if tolerated, usually preferred over other antidiabetic drugs for the first line treatment of type-2 diabetes. The particular decision on which antidiabetic agent to use is based on variables such as efficacy, cost, potential side effects, effects on weight,...
Autores principales: | Tschöpe, Diethelm, Hanefeld, Markolf, Meier, Juris J, Gitt, Anselm K, Halle, Martin, Bramlage, Peter, Schumm-Draeger, Petra-Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664601/ https://www.ncbi.nlm.nih.gov/pubmed/23574917 http://dx.doi.org/10.1186/1475-2840-12-62 |
Ejemplares similares
-
Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients - an analysis of the DiaRegis registry
por: Tschöpe, Diethelm, et al.
Publicado: (2011) -
Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia
por: Bramlage, Peter, et al.
Publicado: (2012) -
Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy – an analysis of the DiaRegis registry
por: Wasem, Jürgen, et al.
Publicado: (2013) -
A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015) -
Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up
por: Bramlage, Peter, et al.
Publicado: (2014)